Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients.
Samantha E ClarkZachary A MarcumJerry RadichRuth EtzioniAnirban BasuPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
Most patients that achieved remission did so by 4 months (120 days) with consistently high adherence, suggesting that this could be a critical time and duration for realizing treatment benefit and patient monitoring. Findings regarding the relationship between adherence and remission can additionally help guide the design of future studies.